Cervical Cancer Medication Update: HYCAMTIN (Topotecan) Approved in Japan
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
- November 30, 2015
- 1 min read
Key highlights:
-
The anti-malignant tumor agent HYCAMTIN (topotecan injectable formulation, manufactured by Nippon Kayaku Co., Ltd.) received approval from Japan's Ministry of Health, Labour and Welfare on November 20, 2015 for the treatment of progressive or recurrent cervical cancer.
-
Development of this drug began on December 13, 2010.
For more information: http://www.nipponkayaku.co.jp/information/detail.php?n=20151120_7WPGFA55
Cervical Cancer
-
Clinical Trial Medications
- (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
- (Lung Cancer) Efficacy of Enhertu in HER2-mutant non-small cell lung cancer (NSCLC).
- (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4